StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a report published on Friday. The firm issued a sell rating on the medical technology company’s stock.
BIOLASE Stock Performance
Shares of BIOL stock opened at $0.15 on Friday. The company has a debt-to-equity ratio of 34.06, a quick ratio of 0.68 and a current ratio of 1.26. BIOLASE has a twelve month low of $0.13 and a twelve month high of $32.09. The stock’s fifty day simple moving average is $0.15 and its 200 day simple moving average is $0.82.
BIOLASE (NASDAQ:BIOL – Get Free Report) last released its earnings results on Thursday, March 21st. The medical technology company reported ($1.76) earnings per share (EPS) for the quarter. BIOLASE had a negative net margin of 41.97% and a negative return on equity of 555.22%. The firm had revenue of $13.49 million during the quarter.
BIOLASE Company Profile
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Featured Stories
- Five stocks we like better than BIOLASE
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- MarketBeat Week in Review – 4/22 – 4/26
- What are earnings reports?
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Invest in Insurance Companies: A Guide
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.
